Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’
Nom du journal : Ann Oncol
Année : 2018
Volume : 29
Page de départ : 758
Page de fin : 765